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A report on the ‘cell-cycle regulation’ minisymposium at the
41st Annual Meeting of the American Society for Cell
Biology, Washington DC, USA, 8-12 December 2001.
At  the  annual  meeting  of  the  American  Society  for  Cell
Biology, several symposia and minisymposia were dedicated
to the coordination of events during the cell cycle. The ‘cell-
cycle regulation’ minisymposium, and indeed the meeting as
a  whole,  seemed  particularly  charged,  given  the  recent
announcement that Leland Hartwell, Paul Nurse and Tim
Hunt  were  recipients  of  the  Nobel  Prize  in  Physiology  or
Medicine “for their discoveries of key regulators of the cell
cycle”. Thus, it was entirely fitting that Nancy Walworth (of
UMDNJ-Robert  Wood  Medical  School,  Piscataway  USA  -
one of the Chairs of the minisymposium) explained at the
beginning of the session the fundamental concepts that each
of  these  three  scientists  introduced,  including  that  of  the
checkpoint. She used this opportunity to segue into a discus-
sion of her most recent work on the regulation of the Chk1
protein  kinase  in  the  fission  yeast,  Schizosaccharomyces
pombe.  (The  regulatory  proteins  mentioned  in  this  article
and their functions in the cell cycle are listed in Table 1.) 
Checkpoints 
Work in Walworth’s laboratory focuses on how the cell cycle
is halted in response to DNA damage, and in particular how
Chk1 may contribute to the maintenance of this ‘checkpoint’
(from which the cell cycle cannot proceed until the damaged
DNA has been repaired). Work from a variety of labs has deter-
mined that the activity of Chk1 inhibits the Cdc25 phosphatase
and activates the Wee1 and Mik1 protein kinases, two actions
that favor phosphorylated, and thus inactive, cyclin-dependent
kinase,  the  engine  that  drives  the  cell  cycle.  Walworth’s
studies indicate the importance of phosphorylation for Chk1
function, which occurs in a checkpoint-dependent manner and
downstream of the action of Rad3p (the fission yeast homolog
of  the  Mec1/ATR  kinase).  Mutation  of  the  phosphorylated
residue  of  Chk1  (Ser345  Ala)  compromises  the  Chk1
protein’s checkpoint function and phenotypically mimics
the  effects  of  a  chk1  deletion.  When  characterizing  the
phosphorylation of  Chk1,  Walworth’s  colleagues  observed
enhanced  nuclear  localization  of  Chk1 following  damage.
Walworth  explained  that  mutation  of  a  putative  nuclear
localization  signal  (NLS,  residues  377-397)  in  Chk1  now
blocked the Chk1 protein’s phosphorylation and rendered it
checkpoint-deficient,  suggesting  that  its  presence  in  the
nucleus is necessary for function. This was confirmed when
they  could  restore  nuclear  localization  and  checkpoint
function to the chk1 NLS-deficient mutant by the addition
of a heterologous NLS, from SV40. Given that a chimera of
wild-type Chk1 fused to the SV40 NLS also showed enrichment
in the nucleus only following DNA damage, the suggestion
was that exit of the Chk1 protein from the nucleus is regu-
lated  in  response  to  DNA  damage.  This  hypothesis  was
supported by the finding that DNA damage stimulated the
association  of  Chk1  with  the  S. pombe  14-3-3  protein,
Rad24.  Mutation  of  the  14-3-3-binding  region  of  Chk1
abolished Rad24 binding as well as DNA-damage-check-
point  function.  This  region  resembles  a  nuclear  export
signal,  suggesting  a  model  in  which  phosphorylation  of
Chk1 stabilizes its interaction with Rad24 in the nucleus,
thereby blocking export of Chk1; this results in accumula-
tion of the Chk1 kinase in the nucleus, where it can  carry
out  its  checkpoint  function  and  keep  cyclin-dependent
kinase inactive. The export signal is not conserved in Chk1
homologs in higher eukaryotes, indicating that this level of
regulation  of  the  DNA-damage  checkpoint  may  not  be
present in these organisms.
Steve Doxsey (University of Massachusetts Medical School,
Worcester, USA) was a late addition to the agenda and did
not appear on the published list of speakers for the mini-
symposium. He made an interesting case for the existence of
a ‘mitotic exit network’ (MEN) in mammalian cells, akin to
the  MEN  in  budding  yeast  and  the  ‘septation initiation
network’  (SIN)  in  fission  yeast.  His  story  begins  with  the
identification  of  two  centrosomal  proteins,  centriolin  andkendrin, that are antigens in the human autoimmune condition
scleroderma;  kendrin  is  a  larger  isoform  of  the  centrosomal
protein  pericentrin.  Immunogold  electron  microscopy  using
anti-centriolin antibodies illustrates its specificity within the
centrosome for the ‘mother’ centriole. Given that both cen-
triolin  and  kendrin  move  to  the  intracellular  bridge  and
midbody during cytokinesis, and recent reports suggest a role
for  the  maternal  centriole  in  cytokinesis,  Doxsey  and  col-
leagues  were  intrigued  by  the  possibility  of  centriolin’s
involvement in cytokinesis. They injected anti-centriolin anti-
bodies  into  Xenopus oocytes  and  observed  cytokinesis
defects; such defects were also seen when centriolin was over-
expressed  in  tissue-culture  cells.  When  small  interfering
RNAs were used to reduce kendrin protein levels, centriolin
was lost from the centriole without a concomitant loss of the
centriolar  proteins   tubulin  or  pericentrin  A;  cytokinesis
defects were observed, but the microtubule-nucleation activ-
ity of centrosomes isolated from these cells was not affected.
These  data  suggest  that  centriolin  and  kendrin  may  be
involved in a regulatory pathway to signal cytokinesis. Doxsey
argued that centriolin is the homolog of the budding yeast
Nud1p (which anchors components of the MEN), on the basis
of its sequence similarity in one specific domain and the inter-
action of this domain with the checkpoint protein Bub2p, as
assessed by yeast two-hybrid protein-protein interaction assay
and by  co-immunoprecipitation when overexpressed. He also
offered the possibility that kendrin may be the homolog of the
fission  yeast  Sid4,  required  for  localization  of  Cdc11  (the
fission yeast homolog of Nud1p and therefore centriolin).
Stephen Elledge (Baylor College of Medicine, Houston, USA)
described recently published work from his lab elucidating the
MEN  of  budding  yeast  and  its  regulation  by  the  polo-like
kinase Cdc5p. His studies indicate that Cdc5p is required to
inactivate  the  GTPase-activating  protein  (GAP)  Bfa1p.  This
inhibition  of  Bfa1p  results  in  the  activation  of  Tem1,  a  Ras-
related GTPase that acts through a series of proteins identified
as  the  MEN  to  accomplish  the  down-regulation  of  cyclin-
dependent kinase activity and the exit from mitosis. He showed
that phosphorylation of Bfa1p coincides with anaphase and this
phosphorylation  is  abolished  in  a  cdc5 mutant.  Elledge  also
suggested that this regulation of Bfa1p is important during the
activation of the spindle-assembly checkpoint, which prevents
cells from dividing until all chromosomes are properly attached
to  the  mitotic  spindle;  cells  treated  with  the  microtubule-
depolymerizing drug nocodazole do not exhibit phosphoryla-
tion of Bfa1p unless the checkpoint is abrogated, as in a strain
with a deletion of the mad2 checkpoint gene. Mad2 binds to
Cdc20,  an  activator  of  the  anaphase-promoting  complex
(APC),  to inhibit APC activity and arrest cells in metaphase in
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Table 1
Cell-cycle regulatory proteins mentioned in this article
Name of protein  Names of homologs Enzymatic function Cell-cycle function
Bfa1 GTPase-activating protein Mitotic exit
Bub2 Checkpoint component
BubR1 Spindle-assembly checkpoint component
Bub3 Spindle-assembly checkpoint component
Cdc20 Activator of the anaphase-promoting complex (APC)
Cdc25 Phosphatase Activates cyclin-dependent kinase (Cdc2) 
Cdc5 Polo-like protein kinase Mitotic exit
Cdh1 Activator of the anaphase-promoting complex (APC)
Centriolin Centrosome component
Chk1 Protein kinase Checkpoint component
Emi1  Inhibitor of the anaphase-promoting complex (APC)
Ipl1 Aurora-like protein kinase Spindle-assembly checkpoint component
Kendrin Pericentrin* Centrosome component
Mad2 Checkpoint component
Mik1 Protein kinase Inactivates cyclin-dependent kinase (Cdc2)
Mps1 Protein kinase Spindle-assembly checkpoint component
Rad24 14-3-3   DNA-damage checkpoint component
Skp1 Component of a ubiquitin ligase complex, the SCF
Tem1 Ras-related GTPase Mitotic exit
 tubulin  Centrosome component
Wee1 Protein kinase Inactivates cyclin-dependent kinase (Cdc2)
* Pericentrin is a smaller isoform of kendrin. response to checkpoint activation. He mentioned data showing
that the DNA-damage checkpoint also impinged upon regula-
tion of Bfa1p but not via Cdc5p. 
Sue  Biggins  (Fred  Hutchinson  Cancer  Research  Center,
Seattle, USA) continued the focus on checkpoints with her
recently  published  work  ascribing  a  role  for  the  budding
yeast  Aurora-like  kinase,  Ipl1p,  in  the  spindle-assembly
checkpoint.  Initial  analysis  of  the  ipl1 mutant  identified  a
chromosome-segregation defect, attributed to a defect in the
kinetochore  that  allowed  kinetochore  beads  made  in  ipl1
mutant cell extract (centromere DNA on beads is exposed to
cell  extract  to  bind  the  required  kinetochore  proteins)  to
maintain microtubule attachments more stably than those
made  in  wild-type  cell  extract.  Despite  the  kinetochore
defect,  however,  ipl1 mutants  do  not  activate  the  spindle-
assembly  checkpoint  as  most  kinetochore  mutants  do,
leading  Biggins  to  hypothesize  that  either  the  checkpoint
cannot monitor the defect in ipl1 mutants or Ipl1p itself is
involved in the checkpoint. The latter model proved correct:
if  the  checkpoint  is  constitutively  active,  as  it  is  when  the
protein kinase Mps1p is overexpressed, inactivation of Ipl1p
results in abrogation of the checkpoint. When the checkpoint
is activated by a microtubule-depolymerizing drug, such as
benomyl, loss of IPL1 function has no effect, suggesting that
Ipl1p is not involved in monitoring the attachment of kineto-
chores to microtubules. Instead, Ipl1p might monitor tension
at the kinetochore - the pulling forces of the spindle at the
kinetochore opposed by the linkage that keeps sister chro-
matids  together.  Recent  reports  have  illustrated  that  the
absence of a sister chromatid (in the cdc6 deletion mutant) or
the  loss  of  linkage  between  sister  chromatids  (in  the
mcd1/scc1  mutant)  activates  the  spindle-assembly  check-
point. Biggins tested whether this activation was IPL1 depen-
dent - and it was, indicating that Ipl1p is required to activate
the checkpoint under conditions in which there is no tension.
Consistent with this role, Ipl1p localizes to kinetochores.
Promoting anaphase 
Valerie Sudakin, a member of Tim Yen’s laboratory at Fox
Chase Cancer Center (Philadelphia, USA), offered a shift in
the focus of talks to the regulation of a key cell-cycle player,
the  APC.  The  APC  is  a  multi-subunit  ubiquitin  ligase  that
targets specific proteins for destruction during key transitions
of the cell cycle; for this reason, it is itself often the target of
checkpoint  pathways,  such  as  the  spindle-assembly  check-
point. Sudakin chronicled the efforts that members of the Yen
lab have made to understand how the proteins involved in the
spindle-assembly checkpoint inhibit APC activity and effect
metaphase  arrest.  They  have  identified  a  multi-protein
complex, named the mitotic checkpoint complex (MCC), that
inhibits the APC’s activity in vitro. This complex consists of
BubR1, Bub3, Mad2 (all known components of the spindle-
assembly checkpoint) and Cdc20, and its inhibitory activity
is 3,000-fold greater than that of Mad2 protein alone. The
complex exists in interphase but can only act on the mitotic
APC, suggesting an additional level of regulation that is not
yet  characterized.  Furthermore,  Yen  and colleagues  have
data suggesting that chromosomes prolong the inhibition of
the APC by the MMC, by stabilizing the interaction between
the two complexes. Sudakin proposed a model in which the
MCC, already formed in interphase, allows rapid inhibition of
the APC until anaphase; the checkpoint maintains this inhi-
bition  if  chromosomes  have  kinetochores  that  are  not
attached to microtubules.
Peter Jackson (Stanford University, USA) elaborated on the
function of Emi1, a protein his lab has identified as a novel
APC inhibitor. He and his colleagues have found that Emi1
degradation is required for APC-mediated destruction of the
mitotic cyclins, A and B, to occur in Xenopus egg extracts.
Immunodepletion  of  Emi1  results  in  early  destruction  of
cyclin B; this phenotype can be rescued with recombinant
Emi1  and  a  non-destructible  cyclin  B  fragment  (the  90
fragment)  that  constitutively  activates  cyclin-dependent
kinase. The amino terminus of Emi1 confers instability; the
addition of a non-destructible Emi1 to cell extract produces a
mitotic arrest with high cyclin levels and an inactive APC.
The Emi1 protein accomplishes its inhibition of the APC by
antagonizing substrate binding, as a result of an interaction
between Emi1 and the first 100 amino acids of the APC acti-
vator Cdc20. Jackson and colleagues further characterized
this interaction between Cdc20 and Emi1 when they began
investigating  the  role  of  Emi1  in  meiotic  cytostatic  factor
(CSF)  arrest;  Xenopus eggs  maintain  this  metaphase  II
arrest  as  they  await  fertilization,  and CSF  arrest  is
Ca2+-labile.  Immunodepletion  of  Emi1  from  CSF-arrested
Xenopus  egg  extracts  resulted  in  continuation  of  the  cell
cycle without Ca2+ addition; they could rescue this pheno-
type with the addition of the carboxyl terminus of the Emi1
protein, which binds Cdc20. Subsequent analysis revealed
that  with  the  addition  of  Ca2+ in  a  normal  exit  from  CSF
arrest,  Emi1  dissociates  from  Cdc20  and  assumes  a  form
that  has  slower  electrophoretic  mobility.  In  vitro,  Emi1  is
phosphorylated  by  Ca2+-calmodulin-dependent  protein
kinase  type  II  (CaMKII),  a  kinase  involved  in  the  signal
transduction cascade that achieves exit from CSF arrest, and
this inhibits the ability of Emi1 to associate with Cdc20.
The  final  speaker  was  Nagi  Ayad,  a  member  of  Marc
Kirschner’s laboratory at Harvard Medical School (Boston,
USA). He described the characterization of a novel APC sub-
strate that regulates mitotic exit; his story provided a beauti-
ful illustration of multiple regulatory mechanisms acting in
concert to control the primary cell-cycle engine, the cyclin-
dependent kinase Cdc2. Using a small-pool cDNA expres-
sion-screening  strategy  in  Xenopus egg  extracts,  he  was
interested in finding new APC substrates that were specifi-
cally targeted for destruction by APC(Cdh1), a version of the
APC  primarily  active  in  G1  of  the  cell  cycle.  Cdh1  is,  like
Cdc20, an APC activator; in addition to conferring activity,
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http://genomebiology.com/2002/3/4/reports/4009.3Cdc20 and Cdh1 confer differential substrate recognition on
the APC ubiquitin ligase that must modify different proteins
at different points during the cell cycle. Ayad and colleagues
identified a novel protein, p66, which is expressed throughout
embryogenesis  in  Xenopus and  has  human,  mouse  and
Drosophila homologs.  It  is  a  true  substrate  for  APC(Cdh1),
because mutation of the motif that is recognized by Cdh1 (the
‘KEN box’) or the addition of a proteasome inhibitor and
90-cyclin  B  results  in  p66  stability.  The  human  p66  is
degraded at mitotic exit and associates with Skp1, a component
of  another  ubiquitin  ligase  complex,  the  SCF  (Skp1-
Cul1/Cdc53-F-box); an  adaptor  protein,  the  F-box  subunit,
confers substrate specificity on this complex. The p66 protein
contains an F-box domain, and deletion of this region abol-
ishes its interaction with Skp1; expression of this mutant in
human cells or addition of it to Xenopus extracts produces a
mitotic  block  (with  stabilization  of  the  Wee1  kinase  and
prolonged phosphorylation of Cdc2). Wee1 and p66 associate
with each other, but this association is dependent on phos-
phorylation of Wee1; mutation of the phosphorylation site
(Ser38 Ala) abrogates the association of Wee1 with p66
and recapitulates the p66 F-box mutant phenotype, namely
stabilization of Wee1. The model proposed by Ayad and
colleagues involves the destruction of p66 by APC(Cdh1)
throughout  the  G1  phase  of  the  cell  cycle,  to  allow  for
Wee1 accumulation and Cdc2 inactivation; but APC inacti-
vation results in p66 accumulation, Wee1 degradation and
Cdc2 activation.
The driving force of the cell cycle is cyclin-dependent kinase
activity. Key steps in regulating the cell cycle must therefore
impinge upon the activity of cyclin-dependent kinase. The cell-
cycle  regulation  minisymposium  18  at  this  year’s  American
Society for Cell Biology conference highlighted the many and
diverse mechanisms the cell employs to control its division
cycle and ensure the production of genetically identical and
viable progeny.
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